Short-term angiotensin-1 receptor antagonism in type 2 diabetic Goto-Kakizaki rats normalizes endothelin-1-induced mesenteric artery contraction

Peptides

Volumn 31, Issue 4, 2010, Pages 609-617

  Matsumoto, Takayuki ^a   Ishida, Keiko ^a   Taguchi, Kumiko ^a   Kobayashi, Tsuneo ^a   Kamata, Katsuo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Angiotensin II; Diabetes; Endothelin 1; ERK; GK rat; Losartan; Mesenteric artery

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN II; ENDOTHELIN 1; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE 1; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; CONTROLLED STUDY; DIABETIC ANGIOPATHY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GOTO KAKIZAKI RAT; MALE; MESENTERIC ARTERY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; SHORT COURSE THERAPY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENDOTHELIN-1; INSULIN; LOSARTAN; MALE; MESENTERIC ARTERIES; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE; RATS; RATS, MUTANT STRAINS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1;

RATTUS; RATTUS NORVEGICUS;

EID: 77649234517     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.12.017     Document Type: Article

References (68)

1. Bisbis S., Bailbe D., Tormo M.A., Picarel-Blanchot F., Derouet M., Simon J., et al. Insulin resistance in the GK rat: decreased receptor number but normal kinase activity in liver. Am J Physiol 265 (1993) E807-E813
2. Candido R., Jandeleit-Dahm K.A., Cao Z., Nesteroff S.P., Burns W.C., Twigg S.M., et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106 (2002) 246-253
3. Cardillo C., Kilcoyne C.M., Cannon Jr. R.O., and Panza J.A. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 35 (2000) 1237-1241
4. Cheetham C., Collis J., O'Driscoll G., Stanton K., Taylor R., and Green D. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol 36 (2000) 1461-1466
5. Cheetham C., O'Driscoll G., Stanton K., Taylor R., and Green D. Losartan, an angiotensin type 1 receptor antagonist, improves conduit vessel endothelial function in type II diabetes. Clin Sci 100 (2001) 13-17
6. Cheng Z.J., Vaskonen T., Tikkanen I., Nurminen K., Ruskoaho H., Vapaatalo H., et al. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension 37 (2001) 433-439
7. Cohen R.A. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis 38 (1995) 105-128
8. De Vriese A.S., Verbeuren T.J., Van de Voorde J., Lameire N.H., and Vanhoutte P.M. Endothelial dysfunction in diabetes. Br J Pharmacol 130 (2000) 963-974
9. d'Uscio L.V., Shaw S., Barton M., and Luscher T.F. Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function. Hypertension 31 (1998) 1305-1310
10. Emori T., Hirata Y., Ohta K., Kanno K., Eguchi S., Imai T., et al. Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension 18 (1991) 165-170
11. Fukui T., Ishizaka N., Rajagopalan S., Laursen J.B., Capers IV Q., Taylor W.R., et al. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80 (1997) 45-51
12. Gauguier D., Froguel P., Parent V., Bernard C., Bihoreau M.T., Portha B., et al. Chromosomal mapping of genetic loci associated with non-insulin dependent diabetes in the GK rat. Nat Genet 12 (1996) 38-43
13. Giacchetti G., Sechi L.A., Rilli S., and Carey R.M. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 16 (2005) 120-126
14. Giachini F.R., Zemse S.M., Carneiro F.S., Lima V.V., Carneiro Z.N., Callera G.E., et al. Interleukin-10 attenuates vascular responses to endothelin-1 via effects on ERK1/2-dependent pathway. Am J Physiol Heart Circ Physiol 296 (2009) H489-H496
15. Goto K., Hama H., and Kasuya Y. Molecular pharmacology and pathophysiological significance of endothelin. Jpn J Pharmacol 72 (1996) 261-290
16. Goto Y., Kakizaki M., and Masaki N. Production of spontaneous diabetic rats by repetition of selective breeding. Tohoku J Exp Med 119 (1976) 85-90
17. Harris A.K., Elgebaly M.M., Li W., Sachidanandam K., and Ergul A. Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes. Am J Physiol Regul Integr Comp Physiol 294 (2008) R1213-R1219
18. Hattori Y., Kawasaki H., and Kanno M. Increased contractile response to endothelin-1 and U46619 via a protein kinase C-mediated nifedipine-sensitive pathway in diabetic rat aorta. Res Commun Mol Pathol Pharmacol 104 (1999) 73-80
19. Iida K.T., Kawakami Y., Suzuki M., Shimano H., Toyoshima H., Sone H., et al. Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am J Physiol Endocrinol Metab 284 (2003) E1125-E1130
20. Imai T., Hirata Y., Emori T., Yanagisawa M., Masaki T., and Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 19 (1992) 753-757
21. Jesmin S., Hattori Y., Maeda S., Zaedi S., Sakuma I., and Miyauchi T. Subdepressor dose of benidipine ameliorates diabetic cardiac remodeling accompanied by normalization of upregulated endothelin system in rats. Am J Physiol Heart Circ Physiol 290 (2006) H2146-H2154
22. Kawaguchi H., Sawa H., and Yasuda H. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J Mol Cell Cardiol 22 (1990) 839-842
23. Kim S., and Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52 (2000) 11-34
24. Kleinbongard P., Dejam A., Lauer T., Jax T., Kerber S., Gharini P., et al. Plasma nitite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med 40 (2006) 295-302
25. Kobayashi T., Hayashi Y., Taguchi K., Matsumoto T., and Kamata K. ANG II enhances contractile responses via PI3-kinase p110 delta pathway in aortas from diabetic rats with systemic hyperinsulinemia. Am J Physiol Heart Circ Physiol 291 (2006) H846-H853
26. Kobayashi T., Matsumoto T., Ooishi K., and Kamata K. Differential expression of alpha2D-adrenoceptor and eNOS in aortas from early and later stages of diabetes in Goto-Kakizaki rats. Am J Physiol Heart Circ Physiol 287 (2004) H135-H143
27. Kobayashi T., Nogami T., Taguchi K., Matsumoto T., and Kamata K. Diabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERK. Br J Pharmacol 155 (2008) 974-983
28. Kobayashi T., Taguchi K., Yasuhiro T., Matsumoto T., and Kamata K. Impairment of PI3-K/Akt pathway underlies attenuated endothelial function in aorta of type 2 diabetic mouse model. Hypertension 44 (2004) 956-962
29. Lerma A., Sandok E.K., Hildebrand Jr. F.L., and Burnerr Jr. J.C. Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction. Circulation 85 (1992) 1894-1898
30. Matsumoto T., Ishida K., Kobayashi T., and Kamata K. Pyrrolidine dithiocarbamate reduces vascular prostanoid-induced responses in aged type 2 diabetic rat model. J Pharmacol Sci 110 (2009) 326-333
31. Matsumoto T., Ishida K., Nakayama N., Kobayashi T., and Kamata K. Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat. Am J Physiol Heart Circ Physiol 296 (2009) H1388-H1397
32. Matsumoto T., Ishida K., Taguchi K., Kobayashi T., and Kamata K. Mechanisms underlying enhanced vasorelaxant response to protease-activated receptor 2-activating peptide in type 2 diabetic Goto-Kakizaki rat mesenteric artery. Peptides 30 (2009) 1729-1734
33. Matsumoto T., Kakami M., Kobayashi T., and Kamata K. Gender differences in vascular reactivity to endothelin-1 (1-31) in mesenteric arteries from diabetic mice. Peptides 29 (2008) 1338-1346
34. Matsumoto T., Kobayashi T., and Kamata K. Alterations in EDHF-type relaxation and phosphodiesterase activity in mesenteric arteries from diabetic rats. Am J Physiol Heart Circ Physiol 285 (2003) H283-H291
35. Matsumoto T., Kobayashi T., Wakabayashi K., and Kamata K. Cilostazol improves endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from diabetic rats. Am J Physiol Heart Circ Physiol 289 (2005) H1933-H1940
36. Matsumoto T., Nakayama N., Ishida K., Kobayashi T., and Kamata K. Eicosapentaenoic acid improves imbalance between vasodilator and vasoconstrictor actions of endothelium-derived factors in mesenteric arteries from rats at chronic stage of type 2 diabetes. J Pharmacol Exp Ther 329 (2009) 324-334
37. Matsumoto T., Noguchi E., Ishida K., Kobayashi T., Yamada N., and Kamata K. Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes. Am J Physiol Heart Circ Physiol 295 (2008) H1165-H1176
38. Matsumoto T., Noguchi E., Kobayashi T., and Kamata K. Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats. Free Radic Biol Med 42 (2007) 993-1007
39. Matsumoto T., Wakabayashi K., Kobayashi T., and Kamata K. Diabetes-related changes in cAMP-dependent protein kinase activity and decrease in relaxation response in rat mesenteric artery. Am J Physiol Heart Circ Physiol 287 (2004) H1064-H1071
40. Matsumoto T., Yoshiyama S., Kobayashi T., and Kamata K. Mechanisms underlying enhanced contractile response to endothelin-1 in diabetic rat basilar artery. Peptides 25 (2004) 1985-1994
41. Mehta P.K., and Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292 (2007) C82-C97
42. Miyauchi T., and Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 61 (1999) 391-415
43. Movassat J., Saulnier C., Serradas P., and Portha B. Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat. Diabetologia 40 (1997) 916-925
44. Oelze M., Daiber A., Brandes E.P., Hortmann M., Wenzel P., Hink U., et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 48 (2006) 677-684
45. Ortiz M.C., Sanabria E., Manriquez M.C., Romero J.C., and Juncos L.A. Role of endothelin and isoprostanes in slow pressor responses to angiotensin II. Hypertension 37 (2001) 505-510
46. Ostenson C.G., Khan A., Abdel-Halim S.M., Guenifi A., Suzuki K., Goto Y., et al. Abnormal insulin secretion and glucose metabolism in pancreatic islets from the spontaneously diabetic GK rat. Diabetologia 36 (1993) 3-8
47. Perkins B.A., Aiello L.P., and Krolewski A.S. Diabetes complications and the renin-angiotensin system. N Engl J Med 361 (2009) 83-85
48. Pieper G.M., and Siebeneich W. Temocapril, an angiotensin converting enzyme inhibitor, protects against diabetes-induced endothelial dysfunction. Eur J Pharmacol 403 (2000) 129-132
49. Pollock D.M. Endothelin, angiotensin, and oxidative stress in hypertension. Hypertension 45 (2005) 477-480
50. Portha B., Serradas P., Bailbe D., Suzuki K., Goto Y., and Giroix M.H. Beta-cell insensitivity to glucose in the GK rat, a spontaneous nonobese model for type II diabetes. Diabetes 40 (1991) 486-491
51. Prasad A., Tupas-Habib T., Schenke W.H., Mincemoyer R., Panza J.A., Waclawin M.A., et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 101 (2000) 2349-2354
52. Rask-Madsen C., and King G.L. Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 3 (2007) 46-56
53. Rubanyi G.M., and Polokoff M.A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, pathophysiology. Pharmacol Rev 46 (1994) 325-415
54. Sachidanandam K., Elgebaly M.M., Harris A.K., Hutchinson J.R., Mezzetti E.M., Portik-Dobos V., et al. Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes. Am J Physiol Heart Circ Physiol 294 (2008) H2743-H2749
55. Sachidanandam K., Hutchinson J.R., Elgebaly M.M., Mezzetti E.M., Dorrance A.M., Motamed K., et al. Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1. Am J Physiol Regul Integr Comp Physiol 296 (2009) R952-R959
56. Skrbic R., and Igic R. Seven decades of angiotensin (1939-2009). Peptides 30 (2009) 1945-1950
57. Sowers J.R. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286 (2004) H1597-H1602
58. Sung C.P., Arleth A.J., Storer B.L., and Ohlstein E.H. Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther 271 (1994) 429-437
59. Taguchi K., Kobayashi T., Hayashi Y., Matsumoto T., and Kamata K. Enalapril improves impairment of SERCA-derived relaxation and enhancement of tyrosine nitration in diabetic rat aorta. Eur J Pharmacol 556 (2007) 121-128
60. Touyz R.M., and Schiffrin E.L. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52 (2000) 639-672
61. Watts S.W. 5-Hydroxytryptamine-induced potentiation of endothelin-1- and norepinephrine-induced contraction is mitogen-activated protein kinase pathway dependent. Hypertension 35 (2000) 244-248
62. Webb M.L., Dickinson K.E., Delaney C.L., Liu E.C., Serafino R., Cohen R.B., et al. The endothelin receptor antagonist, BQ-123, inhibits angiotensin II-induced contractions in rabbit aorta. Biochem Biophys Res Commun 185 (1992) 887-892
63. Wenzel R.R., Ruthemann J., Bruck H., Schafers R.F., Michel M.C., and Philipp T. Endothelin-a receptor antagonist inhibits angiotensin II and noradrenaline in man. Br J Clin Pharmacol 52 (2001) 151-157
64. Yamazaki T., Komuro I., Kudoh S., Zou Y., Shiojima I., Hiroi Y., et al. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem 271 (1996) 3221-3228
65. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415
66. Yoshida K., Yasujima M., Kohzuki M., Kanazawa M., Yoshinaga K., and Abe K. Endothelin-1 augments pressor response to angiotensin II infusion in rats. Hypertension 20 (1992) 292-297
67. Zhou M.S., and Schulman I.H. Prevention of diabetes in hypertensive patients: results and implications from the VALUE trial. Vasc Health Risk Manag 5 (2009) 361-368
68. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787